Millennium Management LLC has recently announced that it has increased stake in Aeglea BioTherapeutics Inc. (NASDAQ:AGLE) by 19.32%. After grabbing 3.74 million shares, the institutional investor is now in possession of 0.61 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 5.71% having worth around $0.63 million.
Aeglea BioTherapeutics Inc. (AGLE) concluded trading on 05/24/23 at a closing price of $0.14, with 0.97 million shares of worth about $0.14 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -88.65% during that period and on Wednesday the price saw a loss of about -4.79%. Currently the company’s common shares owned by public are about 94.26M shares, out of which, 60.28M shares are available for trading.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
Sponsored
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 2 times over the past 12 months. They bought 118,200 shares in 2 of the transactions. In 0 selling transactions, insiders dumped 0 shares.
Pictet – Biotech, Vanguard Total Stock Market ETF, and FCP Medical – BioHealth are the top 3 mutual funds which are holding stakes in Aeglea BioTherapeutics Inc. Pictet – Biotech is currently holding 1.43 million shares of worth totaling $0.24 million. The company recently came buying 0.0 shares which brought its stake up to 2.18% of the company’s outstanding shares. FCP Medical – BioHealth, after buying 0.78 million shares, have now control over 1.19% of the stake in the company. It holds 0.0 shares of worth $0.13 million.
However, the stock later moved at a day high price of 0.1498, or with a loss of -4.79%. Stock saw a price change of -4.67% in past 5 days and over the past one month there was a price change of -10.18%. Year-to-date (YTD), AGLE shares are showing a performance of -68.22% which decreased to -90.47% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.14 but also hit the highest price of $1.64 during that period. The average intraday trading volume for Aeglea BioTherapeutics Inc. shares is 759.68K. The stock is currently trading -8.73% below its 20-day simple moving average (SMA20), while that difference is down -33.70% for SMA50 and it goes to -71.16% lower than SMA200.
Millennium Management LLC acquired 3.74 million shares of Aeglea BioTherapeutics Inc. having value of about $0.63 million. Data submitted at the U.S SEC by Millennium Management LLC revealed that the firm now holds 0.61 million shares in the company valued at close to $84700.56, or have control over 19.32% stake in the company. Aeglea BioTherapeutics Inc. (NASDAQ: AGLE) currently have 94.26M outstanding shares and institutions hold larger chunk of about 78.80% of that. Holding of mutual funds in the company is about 43.27% while other institutional holders and individual stake holders have control over 9.69% and 17.80% of the stake respectively.
The stock has a current market capitalization of $9.40M and its 3Y-monthly beta is at 1.74. It has posted earnings per share of -$0.86 in the same period. It has Quick Ratio of 3.50 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for AGLE, volatility over the week remained 6.72% while standing at 6.72% over the month.
Analysts are in expectations that Aeglea BioTherapeutics Inc. (AGLE) stock would likely to be making an EPS of -$0.15 in the current quarter, while forecast for next quarter EPS is -$0.08 and it is -$0.08 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.15 which is -$0.15 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.27 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 0.60% while it is estimated to increase by 78.00% in next year.
